BIOA

BioAge LabsD

Nasdaq / Pharmaceuticals, Biotechnology & Life Sciences

Quote time unavailable

View Chart

AI scenario view

RankAlpha Sentiment Codex

B+

Bull case

20%

Probability

Target price

$9.00

Analysis reference price unavailable

Analysis 2026-10-17 · RankAlpha Sentiment Codex

Base case

35%

Probability

Target price

$4.80

Analysis reference price unavailable

Analysis 2026-10-17 · RankAlpha Sentiment Codex

Most likely

B-

Bear case

45%

Probability

Target price

$2.00

Analysis reference price unavailable

Analysis 2026-10-17 · RankAlpha Sentiment Codex

The current persistence contract does not provide an exact AI reference price. RankAlpha therefore does not calculate scenario return from the live quote. How scenarios are presented

AI sentiment snapshot

Latest data as of 2026-10-17

AI commentary

The October 2 filing adds a defined QUELL-DME Phase 2 design and second-half 2027 timing, but does not resolve efficacy. The supplied price anchor is $4.84 on October 16. A verified post-filing price-reaction explanation and current analyst revisions are unavailable. The zero-valued sentiment fields denote unavailable measurements, not neutral readings. The deterministic prior is negative; low coverage favors monitoring rather than a bullish inference. [#8-K-2026-10-02] https://www.sec.gov/Archives/edgar/data/1709941/000119312526412300/bioa-20261002.htm

RankAlpha Sentiment Codex - 2026-10-17

Open full AI memo

Evidence flagged

No evidence quality warning is currently attached to this memo.

Impact

standard

Confidence

AI events

2026-12-31eventQUELL-CV Phase 2 topline dataHigh impact

BioAge expects BGE-102 data in the second half of 2026. The primary endpoint is change in hsCRP, a biomarker; a favorable result would support dose selection but would not establish clinical benefit. [#SEC-8K-2026-08-05] https://www.sec.gov/Archives/edgar/data/1709941/000119312526335368/bioa-ex99_1.htm

2026-12-31eventFirst APJ-program IND filingHigh impact

BioAge stated that it intends to file its first investigational new drug application for an APJ program by year-end 2026. Filing would mark development progress, not efficacy. [#SEC-8K-2026-08-05] https://www.sec.gov/Archives/edgar/data/1709941/000119312526335368/bioa-ex99_1.htm

2027-12-31catalystQUELL-DME Phase 2 topline dataHigh impact

The October 2 filing confirms first dosing in an approximately 180-participant trial and anticipates results in the second half of 2027. Its visual-acuity endpoint tests a clinical outcome; the trial remains early proof of concept. [#8-K-2026-10-02] https://www.sec.gov/Archives/edgar/data/1709941/000119312526412300/bioa-20261002.htm

View full catalyst timeline

Recommendation

N/A

No formal recommendation provided.

Open AI Memo

As of 2026-10-17 • Updated nightlySource: Internal modelMethodology